The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2020Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease
Study Rationale:
Neurosteroids are substances that occur naturally in the brain and help regulate and modulate the activity of brain cells. In previous studies, the investigators demonstrated that... -
Access to Data and Biospecimens, 2020Development of a Biomarker Platform for Parkinson’s Disease Using Patient-derived Cells
Study Rationale:
Inadequate understanding of how Parkinson's disease develops is a major roadblock in developing effective therapeutics and methods to diagnose the disease earlier. This project... -
Improved Biomarkers and Clinical Outcome Measures, 2020Assessment of Brain Tau Burden in Parkinson's Disease with or without a LRRK2 Mutation using [18F]MK-6240 PET Imaging
Study Rationale:
The precise mechanisms of cellular damage in Parkinson's disease remain unclear. Research has shown that abnormal forms of the protein alpha-synuclein accumulates in brain cells in... -
Therapeutic Pipeline Program, 2020Target Validation Studies for the Discovery of Novel Small Molecule Therapeutics with the Potential to Modify Disease Outcome by Inhibiting Bacterial Amyloid Protein-induced Alpha-synuclein Aggregation and Associated Neuronal Toxicity
Study Rationale:
Patients with Parkinson’s disease frequently report serious gastrointestinal (GI) symptoms, most commonly constipation, which are not well treated with currently available medicine... -
Improved Biomarkers and Clinical Outcome Measures, 2020Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease
Study Rationale:
Currently, there are no tools to predict whether someone is at risk of developing Parkinson’s disease or to diagnose the early stages of the disease before motor symptoms can be... -
Target Advancement Program, 2020Determining the Ligase and DUB Landscape of Mitochondrial and Alpha-synuclein Turnover
Study Rationale:
Research suggests that accumulation of faulty mitochondria (the “powerhouse” of the cell) or mutated forms of the protein alpha-synuclein in the brain contribute to the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.